Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA

Conditions studied

Cancer, Solid Tumor, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Targeted Therapy, Chemotherapy, Immunotherapy, Precision Therapy

About this study

Solid tumors pose significant challenges in current therapeutic approaches. Targeted therapy has emerged as a promising avenue, aiming to enhance treatment efficacy while minimizing adverse effects. This clinical trial focuses on an innovative combination of two targeted inhibitors, Palbociclib and Bevacizumab, for their potential synergistic effects in addressing these challenging malignancies. Moreover, this study incorporates a molecular approach by considering Long Non-Coding RNAs (LncRNAs) as biomarkers. Initiating with a focus on colorectal cancer, the study aims to expand its scope to other solid tumors, including lung, breast, ovarian and other cancers. Palbociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, disrupts the cell cycle progression, particularly in cancer cells with specific molecular characteristics. Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, targets angiogenesis-a critical process for tumor growth and metastasis. The rationale behind combining these agents lies in their complementary mechanisms of action, potentially leading to enhanced antitumor effects. LncRNAs have shown promise in predicting treatment response and prognosis in various cancers, providing an additional layer of precision to the treatment strategy. By elucidating the molecular basis through LncRNA analysis, the trial aims to tailor the treatment to the specific molecular profile of each patient, ultimately striving for better outcomes and improved survival rates. This novel combination therapy, coupled with a personalized biomarker-driven approach, represents a cutting-edge strategy in the pursuit of more effective and individualized treatment for solid tumors.

Interventions

• Genetic: SNP — Diagnostics of patients' carriers or not of the risk allele(s)
• Drug: Palbociclib 125mg — Palbociclib 125mg/day/os over 21 days every 28 days
• Drug: Bevacizumab — 10mg/kg every 21 days

Primary outcomes

• Assessment of Cancer Progression ([Time Frame: up to 60 months])
• Identification of Potential Biomarkers ([ Time Frame: Once at the moment of the patient's enrollment in the study])
• Evaluation of Treatment Response to Palbociclib and Bevacizumab Combination Therapy ([ Time Frame: up to 60 months])

Eligibility information

Study locations

• Haykel Hospital, Tripoli, North Lebanon 961 Lebanon
• Lebanese University, Tripoli, North Lebanon 961 Lebanon